From: Efficacy of Helicobacter pylori eradication regimens in Rwanda: a randomized controlled trial
Characteristics | Total (n = 229) | CLARITHRO n = 6127% | CIPRO n = 5624% | METRO n = 5725% | CIPRO-Plus n = 5524% | |
---|---|---|---|---|---|---|
Demographic characteristics | Male (%) | 35 | 43 | 43 | 35 | 35 |
Age, years mean ± SD | 42 ± 16 | 40 ± 15 | 44 ± 16 | 41 ± 16 | 41 ± 17 | |
Married (%) | 57 | 52 | 68 | 60 | 49 | |
CommunityHealth Insurance (%) | 88 | 85 | 88 | 93 | 87 | |
Access to endoscopy (days) | 2.2 ± 3.1 | 1.9 ± 0.6 | 2.8 ± 6 | 2.3 ± 1.7 | 1.9 ± 0.6 | |
Medical history | PPI or H2 blocker before (%) | 77 | 74 | 79 | 79 | 78 |
Triple therapy before (%) | 17 | 13 | 23 | 16 | 18 | |
Antibiotics before (%) | 14 | 13 | 13 | 13 | 18 | |
Symptoms | Epigastric pain (%) | 96 | 97 | 95 | 95 | 96 |
Vomiting (%) | 30 | 27 | 38 | 19 | 35 | |
Hematemesis (%) | 8 | 10 | 9 | 4 | 9 | |
Melena (%) | 2 | 2 | 4 | 2 | 2 | |
Endoscopy finding | Normal endoscopy (%) | 16 | 18 | 14 | 21 | 11 |
Gastritis (%) | 56 | 41 | 55 | 61 | 67 | |
Gastric ulcer (%) | 11 | 10 | 14 | 14 | 7 | |
Duodenal ulcer (%) | 30 | 41 | 36 | 25 | 16 | |
Initially positive FAT (%) | 37 | 39 | 39 | 39 | 31 | |
Baseline HRQoLtotal group(mean ± SD score) | 76 ± 11 | 77 ± 13 | 76 ± 12 | 76 ± 8 | 78 ± 12 | |
Baseline HRQoLin functional dyspepsia (n = 37) (mean ± SD score) | 73 ± 12 | 71 ± 9 | 70 ± 17 | 74 ± 10 | 76 ± 14 |